L-689,560 je antagonist NMDA receptora.[3]

L-689,560
5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
Nazivi
Preferisani IUPAC naziv
5,7-dihloro-4-(fenilkarbamoilamino)-1,2,3,4-tetrahidrohinolin-2-karboksilna kiselina
Drugi nazivi
  • 4-trans-2-karboksi-5,7-dihloro-4-fenilaminokarbonilamino-1,2,3,4-tetrahidrohinolin
  • L 689560
  • L-689,560
  • L-689560
  • trans-2-karboksi-5,7-dihloro-4-(((fenilamino)karbonil)amino)-1,2,3,4-tetrahidrohinolin
Identifikacija
3D model (Jmol)
  • C1C(C2=C(C=C(C=C2Cl)Cl)NC1C(=O)O)NC(=O)NC3=CC=CC=C3
Svojstva
C17H15Cl2N3O3
Molarna masa 380,23 g·mol−1
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
Reference infokutije

Reference

уреди
  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  уреди
  2. ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1. 
  3. ^ Małgorzata Dybała; Dorota Maciag; Agnieszka Cichy; Lucyna Pomierny-Chamioło; Anna Partyka; Tadeusz Librowski; Gabriel Nowak (2006). „Medium supplementation with zinc enables detection of imipramine-induced adaptation in glycine/NMDA receptors labeled with [3H]L-689,560”. Pharmacol Rep. 58 (5): 753—7.